NCT01443481View on ClinicalTrials.gov

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Solid TumorsHepatic Impairment
Interventions
DRUG

Dovitinib

Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups

Trial Locations (12)

5800

Novartis Investigative Site, Maastricht

9000

Novartis Investigative Site, Ghent

20089

Novartis Investigative Site, Rozzano

20133

Novartis Investigative Site, Milan

27710

Duke University Medical Center DUMC, Durham

30625

Novartis Investigative Site, Hanover

37126

Novartis Investigative Site, Verona

60590

Novartis Investigative Site, Frankfurt

78229

Cancer Therapy & Research Center / UT Health Science Center SC, San Antonio

90095

University of California at Los Angeles Dept. of UCLA (4), Los Angeles

119228

Novartis Investigative Site, Singapore

1066 CX

Novartis Investigative Site, Amsterdam

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY